Human Tumor Antigens and Cancer ImmunotherapyReport as inadecuate

Human Tumor Antigens and Cancer Immunotherapy - Download this document for free, or read online. Document in PDF available to download.

BioMed Research International - Volume 2015 2015, Article ID 948501, 17 pages -

Review Article

Ludwig Institute for Cancer Research, 1200 Brussels, Belgium

WELBIO Walloon Excellence in Life Sciences and Biotechnology, 1200 Brussels, Belgium

de Duve Institute, Université Catholique de Louvain, 1200 Brussels, Belgium

Received 26 November 2014; Accepted 3 March 2015

Academic Editor: Yung-Fu Chang

Copyright © 2015 Nathalie Vigneron. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


With the recent developments of adoptive T cell therapies and the use of new monoclonal antibodies against the immune checkpoints, immunotherapy is at a turning point. Key players for the success of these therapies are the cytolytic T lymphocytes, which are a subset of T cells able to recognize and kill tumor cells. Here, I review the nature of the antigenic peptides recognized by these T cells and the processes involved in their presentation. I discuss the importance of understanding how each antigenic peptide is processed in the context of immunotherapy and vaccine delivery.

Author: Nathalie Vigneron



Related documents